{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:59:46Z","timestamp":1780891186990,"version":"3.54.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Busulfan is an alkylating agent used in combination with other chemotherapeutic agents and has become a common component of conditioning regimens prior to hematopoietic stem cell transplantation. Busulfan has a very narrow therapeutic index corresponding to the area under the plasma concentration\u2013time curve, with supra\u2010therapeutic busulfan levels associated with hepatic and neurologic toxicity and increased transplant\u2010related mortality, while sub\u2010therapeutic levels can be ineffective, resulting in disease relapse or graft failure. Busulfan is believed to be metabolized in the liver via conjugation with glutathione as well as cytochrome P450 isoenzymes. Interactions with medications known to affect CYP3A4, including phenytoin and metronidazole, have been described in multiple instances. This case discusses a drug\u2013drug interaction between busulfan and rifampin, a known CYP3A4 inducer that has limited evidence currently in the literature. Busulfan therapeutic drug monitoring revealed accelerated busulfan clearance determined to be due to rifampin's effect on busulfan metabolism.<\/jats:p>","DOI":"10.1002\/prp2.70230","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:43:59Z","timestamp":1773459839000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Clinically Relevant Drug Interaction Between Busulfan and Rifampin in the Setting of Hematopoietic Stem Cell Transplant Conditioning"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9920-9574","authenticated-orcid":false,"given":"Colleen","family":"Drangines","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, BMT, and Cellular Therapies SSM Health Saint Louis University Hospital; Saint Louis University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Laquet","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, BMT, and Cellular Therapies SSM Health Saint Louis University Hospital; Saint Louis University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranju","family":"Kunwor","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, BMT, and Cellular Therapies SSM Health Saint Louis University Hospital; Saint Louis University School of Medicine  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.489"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.11.029"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3460"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1360277"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02906128"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03034-4"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2122-0"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q087"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217729745"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200504000-00182"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280778"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.06.013"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010850"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2657-8"},{"key":"e_1_2_11_16_1","unstructured":"GRAFAPEX (treosulfan) for injection for intravenous use Initial U.S. Approval: 2025 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/214759s000lbl.pdf accessed June 2 2025."},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30157-7"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010189049"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.04.014"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.776"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70230","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70230","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:44:42Z","timestamp":1780890282000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/prp2.70230"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70230","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70230"}}